Table II.
Survival of patients associated with clinicopathological features and biomarkers.
| Variables | Patients | Events | DFS rate, % | Median ± SE | P (log-rank) | Events | OS rate, % | Median ± SE | P (log-rank) |
|---|---|---|---|---|---|---|---|---|---|
| Age | 0.0938 | 0.0888 | |||||||
| <60 years | 93 | 13 | 14.0 | 84±2.6695592 | 8 | 8.6 | 84±3.1875801 | ||
| >60 years | 29 | 28 | 96.6 | 70±5.4070979 | 14 | 48.3 | 70±6.3744223 | ||
| Tumor size | 0.2281 | 0.3939 | |||||||
| <2.0 | 36 | 3 | 8.3 | 87±5.6198349 | 5 | 13.9 | 87±4.5836602 | ||
| ≥2.0 and ≤5.0 | 78 | 16 | 20.5 | 82±3.6060642 | 26 | 33.3 | 82±3.0635466 | ||
| >5.0 | 6 | 2 | 33.3 | 73±16.0603030 | 3 | 50 | 75±12.8443676 | ||
| Unknown | 12 | 1 | 8.3 | NA | 7 | 58.3 | NA | ||
| Lymph node status | <0.0001a | 0.0062a | |||||||
| Positive | 62 | 7 | 11.3 | 87±2.0293832 | 5 | 8.1 | 87±2.6739158 | ||
| Negative | 55 | 31 | 56.4 | 63±3.8471953 | 14 | 25.5 | 53±4.4754747 | ||
| Unknown | 5 | 3 | 60 | NA | 3 | 60 | NA | ||
| Distant metastasis | <0.0001a | <0.0001a | |||||||
| Positive | 32 | 32 | 100 | 87±2.4340914 | 22 | 68.8 | 88±2.0415520 | ||
| Negative | 90 | 9 | 0.03 | 27±3.5732850 | 0 | 0 | 40.5±3.7709387 | ||
| ER status | 0.0822 | 0.2415 | |||||||
| Positive | 57 | 16 | 28.1 | 87±3.6671959 | 8 | 14.0 | 86±4.1966608 | ||
| Negative | 52 | 22 | 42.3 | 75±3.6619246 | 12 | 23.1 | 73±4.5150288 | ||
| Unknown | 13 | 3 | 23.1 | NA | 2 | 14.4 | NA | ||
| PR status | 0.2300 | 0.6557 | |||||||
| Positive | 40 | 11 | 27.5 | 82±4.7006779 | 7 | 17.5 | 80±5.2390218 | ||
| Negative | 69 | 27 | 39.1 | 79±3.1488219 | 13 | 18.8 | 79±3.9022241 | ||
| Unknown | 13 | 3 | 23.1 | NA | 2 | 15.4 | NA | ||
| HER2 status | 0.0097a | 0.7220 | |||||||
| Positive | 48 | 5 | 10.4 | 60±4.8890965 | 5 | 10.4 | 53±5.6055087 | ||
| Negative | 61 | 32 | 52.5 | 82±2.7297154 | 14 | 23.0 | 80±3.4181057 | ||
| Unknown | 13 | 4 | 30.8 | NA | 3 | 23.1 | NA | ||
| P53 status | 0.1206 | 0.3823 | |||||||
| Positive | 37 | 16 | 43.2 | 82±5.5693640 | 7 | 18.9 | 82±6.3899854 | ||
| Negative | 72 | 22 | 30.6 | 79±2.7109243 | 12 | 16.7 | 79±3.3807911 | ||
| Unknown | 13 | 3 | 23.1 | NA | 2 | 15.4 | NA | ||
| SPHK1 | 0.0001a | 0.0007a | |||||||
| Positive | 64 | 31 | 48.4 | 70±3.6525019 | 18 | 28.1 | 62±4.2430458 | ||
| Negative | 58 | 10 | 17.2 | 88±2.4733977 | 4 | 6.9 | 88±3.1148016 | ||
| Intrinsic subtype | 0.0415a | 0.0005a | |||||||
| Luminal A | 53 | 16 | 30.2 | 86±3.7240436 | 9 | 17.0 | 85.5±4.2700536 | ||
| Luminal B | 8 | 1 | 12.5 | 80±11.8289970 | 0 | 0 | 80±13.0198697 | ||
| HER2 type | 6 | 4 | 66.7 | 59±13.6623570 | 4 | 66.7 | 30±13.9835618 | ||
| Basal-like | 42 | 17 | 40.5 | 75±3.9125198 | 8 | 19.0 | 75±5.0232251 | ||
| Undefined | 13 | 3 | 23.1 | NA | 1 | 7.8 | NA |
a
Statistically significant. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; SPHK1, sphingosine kinase 1; OS, overall survival; DFS, disease-free survival; NA, not applicable; SE, standard error.